| Dr Steven Tsistrakis, MD | |
|
6 Tsienneto Rd Ste 301, Derry, NH 03038-1584 | |
| (603) 432-8802 | |
| Not Available |
| Full Name | Dr Steven Tsistrakis |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 8 Years |
| Location | 6 Tsienneto Rd Ste 301, Derry, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992168389 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 22335 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Parkland Medical Center | Derry, NH | Hospital |
| Elliot Hospital | Manchester, NH | Hospital |
| Androscoggin Valley Hospital | Berlin, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Granite State Gastrointestinal Consultants Pllc | 8022093962 | 7 |
News Archive
As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the International Genomics Consortium (IGC) have launched a new joint venture that will help usher in an age of personalized medicine.
Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced that its lead compound CPI-613 has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch.
Hepatitis E virus infection is once again in the spotlight, with two studies presented today at The International Liver Congress 2018 in Paris, France challenging the ideas that HEV infections are benign and self-limiting, and that blood-borne transmission is a rare event.
Furiex Pharmaceuticals, Inc. today reported its financial and operating results for the quarter ended June 30, 2010. Furiex was spun off from PPD, Inc. effective June 14, 2010. The financial information included in the financial and operating results does not reflect the consolidated results of operations or cash flows of the company had it been a separate, stand-alone entity during the periods presented as the information through June 14, 2010, was derived from PPD's discovery sciences segment.
Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx's proprietary technology platform.
› Verified 8 days ago
| Entity Name | Androscoggin Valley Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386680593 PECOS PAC ID: 2365350725 Enrollment ID: O20040402000121 |
News Archive
As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the International Genomics Consortium (IGC) have launched a new joint venture that will help usher in an age of personalized medicine.
Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced that its lead compound CPI-613 has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch.
Hepatitis E virus infection is once again in the spotlight, with two studies presented today at The International Liver Congress 2018 in Paris, France challenging the ideas that HEV infections are benign and self-limiting, and that blood-borne transmission is a rare event.
Furiex Pharmaceuticals, Inc. today reported its financial and operating results for the quarter ended June 30, 2010. Furiex was spun off from PPD, Inc. effective June 14, 2010. The financial information included in the financial and operating results does not reflect the consolidated results of operations or cash flows of the company had it been a separate, stand-alone entity during the periods presented as the information through June 14, 2010, was derived from PPD's discovery sciences segment.
Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx's proprietary technology platform.
› Verified 8 days ago
| Entity Name | Androscoggin Valley Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679526644 PECOS PAC ID: 2365350725 Enrollment ID: O20040929000254 |
News Archive
As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the International Genomics Consortium (IGC) have launched a new joint venture that will help usher in an age of personalized medicine.
Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced that its lead compound CPI-613 has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch.
Hepatitis E virus infection is once again in the spotlight, with two studies presented today at The International Liver Congress 2018 in Paris, France challenging the ideas that HEV infections are benign and self-limiting, and that blood-borne transmission is a rare event.
Furiex Pharmaceuticals, Inc. today reported its financial and operating results for the quarter ended June 30, 2010. Furiex was spun off from PPD, Inc. effective June 14, 2010. The financial information included in the financial and operating results does not reflect the consolidated results of operations or cash flows of the company had it been a separate, stand-alone entity during the periods presented as the information through June 14, 2010, was derived from PPD's discovery sciences segment.
Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx's proprietary technology platform.
› Verified 8 days ago
| Entity Name | Granite State Gastrointestinal Consultants Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942214457 PECOS PAC ID: 8022093962 Enrollment ID: O20060925000181 |
News Archive
As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the International Genomics Consortium (IGC) have launched a new joint venture that will help usher in an age of personalized medicine.
Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced that its lead compound CPI-613 has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch.
Hepatitis E virus infection is once again in the spotlight, with two studies presented today at The International Liver Congress 2018 in Paris, France challenging the ideas that HEV infections are benign and self-limiting, and that blood-borne transmission is a rare event.
Furiex Pharmaceuticals, Inc. today reported its financial and operating results for the quarter ended June 30, 2010. Furiex was spun off from PPD, Inc. effective June 14, 2010. The financial information included in the financial and operating results does not reflect the consolidated results of operations or cash flows of the company had it been a separate, stand-alone entity during the periods presented as the information through June 14, 2010, was derived from PPD's discovery sciences segment.
Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx's proprietary technology platform.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven Tsistrakis, MD 6 Tsienneto Rd Ste 301, Derry, NH 03038-1584 Ph: (603) 432-8802 | Dr Steven Tsistrakis, MD 6 Tsienneto Rd Ste 301, Derry, NH 03038-1584 Ph: (603) 432-8802 |
News Archive
As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the International Genomics Consortium (IGC) have launched a new joint venture that will help usher in an age of personalized medicine.
Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced that its lead compound CPI-613 has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch.
Hepatitis E virus infection is once again in the spotlight, with two studies presented today at The International Liver Congress 2018 in Paris, France challenging the ideas that HEV infections are benign and self-limiting, and that blood-borne transmission is a rare event.
Furiex Pharmaceuticals, Inc. today reported its financial and operating results for the quarter ended June 30, 2010. Furiex was spun off from PPD, Inc. effective June 14, 2010. The financial information included in the financial and operating results does not reflect the consolidated results of operations or cash flows of the company had it been a separate, stand-alone entity during the periods presented as the information through June 14, 2010, was derived from PPD's discovery sciences segment.
Ablynx [Euronext Brussels: ABLX] and Spirogen Ltd. announce a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx's proprietary technology platform.
› Verified 8 days ago
Dr. Zachary S Spigelman, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 6 Tsienneto Rd Ste 204, Derry, NH 03038 Phone: 603-421-2156 Fax: 603-421-2307 | |
Dr. Paul Michael Macdonald, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 6 Tsienneto Rd, Suite 300, Derry, NH 03038 Phone: 603-216-0400 Fax: 603-216-3800 | |
Steven Taylor, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 6 Tsienneto Road, Suite 301, Derry, NH 03038 Phone: 603-432-8802 Fax: 603-432-7430 | |
Dr. Knut Roalsvig, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 6 Tsienneto Rd, Suite 301, Derry, NH 03038 Phone: 603-432-8802 Fax: 603-432-7430 | |
Dr. Andrea B Schneebaum, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 6 Tsienneto Rd, Suite 300, Derry, NH 03038 Phone: 603-216-0400 Fax: 603-216-3800 | |
Dr. Laura Jean Fox, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 6 Tsienneto Rd, Suite 300, Derry, NH 03038 Phone: 603-216-0400 Fax: 603-216-3800 | |
Dr. Edmund S Schiavoni Jr., MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 6 Tsienneto Road, Suite 300, Derry, NH 03038 Phone: 603-216-0400 Fax: 603-216-3800 |